Abbott Looks to Consumer for Growth – WSJ.com.
Related articles
- Gilead Shares Rise on Hepatitis C Treatment (minyanville.com)
- Hep C drugs bring high cure rates in trial (todayonline.com)
- Abbott’s three oral hepatitis C drugs produce high cure rates in trial (medcitynews.com)
- Abbot Holding Steady For Long-Term Investments (seekingalpha.com)
- Big Corporate Breakups In 2011 (forbes.com)
- Abbott admits to errors in pharma chief’s college credentials (fiercebiotech.com)
- Abbott Said to Plan Benchmark Bond Offering for AbbVie Spinoff – Bloomberg (bloomberg.com)
- We’ll find billions in savings: Abbott (news.theage.com.au)
- Abbott Laboratories Preps Jumbo $10 Billion-Plus Bond Deal to Fund Spin-off (biospace.com)
- GSK, Abbott drug combo kills triple-negative breast cancer in mice (fiercebiotechresearch.com)